Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hoffman

Showing results (131-140 of 1,212) with videos related to

Pageof 122
Sort By:
JAMA|October 4, 2012
Mexiletine for treatment of myotonia: a trial triumph for rare disease networksEric P Hoffman, Henry J Kaminski
Journal of Molecular Biology|April 14, 1970
Effect of Sul gene dosage on the production of suppressed alkaline phosphatase in Escherichia coli K12E P Hoffman, R C Wilhelm
The Journal of Pediatrics|March 27, 2007
Impaired endothelial function in healthy African-American adolescents compared with CaucasiansMary M Duck, Robert P Hoffman
Journal of the American Chemical Society|March 21, 2025
Competition between Hydrogen and Chalcogen Bonding in Homodimers of Chalcogen Hydrides (H<sub>2</sub>X)<sub>2</sub>, X = O, S, Se, TeMaxwell P Hoffman, Sotiris S Xantheas
Discovery Medicine|November 16, 2013
Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapiesEric P Hoffman, Edward M Connor
Advances in Surgery|October 23, 2009
Preoperative versus postoperative adjuvant therapy for adenocarcinoma of the pancreasJohn P Hoffman, Karyn B Stitzenberg
Journal of Neuromuscular Diseases|November 13, 2023
Reply to F. Muntoni et al.: "In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular DystrophyPaula R Clemens, Eric P Hoffman
Annals of Neurology|May 5, 2021
Concerns Regarding Therapeutic Implications of Very Low-Level DystrophinEric P Hoffman, Paula R Clemens
The Journal of Physical Chemistry. A|December 2, 2025
Engineering the Formation of Chalcogen Bonds with Water: I. Heterodimers of the Chalcogen Hydrides H<sub>2</sub>O-H<sub>2</sub>X (X = S, Se, Te)Maxwell P Hoffman, Sotiris S Xantheas
Journal of Chemical Theory and Computation|May 29, 2026
H<sub>2</sub>X100: A Gold-Standard CCSD(T)/CBS Benchmark Dataset of Binding Energies, Structures, and Harmonic Frequencies for (H<sub>2</sub>X)<i><sub>n</sub></i>, X = S, Se, Te, <i>n</i> = 2-4, and Assessment of Lower-Scaling Density Functional Theory MethodsMaxwell P Hoffman, Sotiris S Xantheas
Pageof 122

Showing results (131-140 of 1,212) with videos related to

Sort By:
Pageof 122
JAMA|October 4, 2012
Mexiletine for treatment of myotonia: a trial triumph for rare disease networksEric P Hoffman, Henry J Kaminski
Journal of Molecular Biology|April 14, 1970
Effect of Sul gene dosage on the production of suppressed alkaline phosphatase in Escherichia coli K12E P Hoffman, R C Wilhelm
The Journal of Pediatrics|March 27, 2007
Impaired endothelial function in healthy African-American adolescents compared with CaucasiansMary M Duck, Robert P Hoffman
Journal of the American Chemical Society|March 21, 2025
Competition between Hydrogen and Chalcogen Bonding in Homodimers of Chalcogen Hydrides (H<sub>2</sub>X)<sub>2</sub>, X = O, S, Se, TeMaxwell P Hoffman, Sotiris S Xantheas
Discovery Medicine|November 16, 2013
Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapiesEric P Hoffman, Edward M Connor
Advances in Surgery|October 23, 2009
Preoperative versus postoperative adjuvant therapy for adenocarcinoma of the pancreasJohn P Hoffman, Karyn B Stitzenberg
Journal of Neuromuscular Diseases|November 13, 2023
Reply to F. Muntoni et al.: "In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular DystrophyPaula R Clemens, Eric P Hoffman
Annals of Neurology|May 5, 2021
Concerns Regarding Therapeutic Implications of Very Low-Level DystrophinEric P Hoffman, Paula R Clemens
The Journal of Physical Chemistry. A|December 2, 2025
Engineering the Formation of Chalcogen Bonds with Water: I. Heterodimers of the Chalcogen Hydrides H<sub>2</sub>O-H<sub>2</sub>X (X = S, Se, Te)Maxwell P Hoffman, Sotiris S Xantheas
Journal of Chemical Theory and Computation|May 29, 2026
H<sub>2</sub>X100: A Gold-Standard CCSD(T)/CBS Benchmark Dataset of Binding Energies, Structures, and Harmonic Frequencies for (H<sub>2</sub>X)<i><sub>n</sub></i>, X = S, Se, Te, <i>n</i> = 2-4, and Assessment of Lower-Scaling Density Functional Theory MethodsMaxwell P Hoffman, Sotiris S Xantheas
Pageof 122